Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03115827 · ClinicalTrials.gov registry record · Phase 4
Norepinephrine-targeted Therapy for Action Control in Parkinson Disease
A Phase 4 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT03115827 is a Phase 4 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 15 participants.
The verdict
NCT03115827, a Phase 4 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether droxidopa, a medication that increases norepinephrine levels, may be effective in improving some aspects of cognition and movement in Parkinson's disease (PD).
Interventions
- DRUG Carbidopa
- DRUG Droxidopa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-04-18 |
| Est. Completion | 2018-12-21 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03115827
The ClinicalTrials.gov registry entry for NCT03115827 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carbidopa is the first listed.
NCT03115827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03115827 about?
NCT03115827 is a clinical study titled "Norepinephrine-targeted Therapy for Action Control in Parkinson Disease". The purpose of this study is to find out whether droxidopa, a medication that increases norepinephrine levels, may be effective in improving some aspects of cognition and movement in Parkinson's disease (PD).
What is the current status of trial NCT03115827?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2017-04-18. Estimated completion is 2018-12-21.
What interventions are being tested in trial NCT03115827?
The interventions under investigation include: Carbidopa (DRUG), Droxidopa (DRUG).
Who is sponsoring clinical trial NCT03115827?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.